RxDoctor Payments Data

Steven Foster, MD

General Practice · Cedar Park, TXNPI 1245276682

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 21 payments — averaging $51.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$392
  • Novo Nordisk$326
  • Astellas Pharma US Inc$120
  • Lilly USA, LLC$87
  • Abbott$85
  • Cranial Technologies, Inc$25
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082 in reported general payments places this provider in the 80th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$84,697
Medicare patients
200
Services billed
17,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$38,658
TrulicityDulaglutide31$30,123
OzempicSemaglutide28$26,500
MounjaroTirzepatide19$19,317
JanuviaSitagliptin Phosphate14$17,823
XareltoRivaroxaban18$16,631
Levothyroxine Sodium261$3,137
Metoprolol Succinate136$2,211
Omeprazole127$2,103
Atorvastatin Calcium262$2,015
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide46$1,805
Fluticasone Propionate79$1,451
Albuterol Sulfate HfaAlbuterol Sulfate62$1,441
Olmesartan Medoxomil49$1,441
Amlodipine Besylate188$1,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$87$49,44050 claims
Novo NordiskOzempic$326$26,50028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,074 general practice providers in Texas.

Other general practice in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →